SG11201407880QA - Treatment of solid tumors using coenzyme q10 - Google Patents
Treatment of solid tumors using coenzyme q10Info
- Publication number
- SG11201407880QA SG11201407880QA SG11201407880QA SG11201407880QA SG11201407880QA SG 11201407880Q A SG11201407880Q A SG 11201407880QA SG 11201407880Q A SG11201407880Q A SG 11201407880QA SG 11201407880Q A SG11201407880Q A SG 11201407880QA SG 11201407880Q A SG11201407880Q A SG 11201407880QA
- Authority
- SG
- Singapore
- Prior art keywords
- lllll
- international
- llll
- coenzyme
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654245P | 2012-06-01 | 2012-06-01 | |
| PCT/US2013/043785 WO2013181639A1 (en) | 2012-06-01 | 2013-05-31 | Treatment of solid tumors using coenzyme q10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407880QA true SG11201407880QA (en) | 2014-12-30 |
Family
ID=49673946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407880QA SG11201407880QA (en) | 2012-06-01 | 2013-05-31 | Treatment of solid tumors using coenzyme q10 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20140017317A1 (ja) |
| EP (1) | EP2854528B8 (ja) |
| JP (3) | JP6352905B2 (ja) |
| KR (2) | KR102163948B1 (ja) |
| CN (1) | CN104507308A (ja) |
| AU (2) | AU2013267166A1 (ja) |
| BR (1) | BR112014029954A2 (ja) |
| CA (2) | CA3090268A1 (ja) |
| EA (1) | EA032345B1 (ja) |
| ES (1) | ES2761449T3 (ja) |
| HK (1) | HK1208995A1 (ja) |
| IL (1) | IL236008B (ja) |
| IN (1) | IN2014DN10734A (ja) |
| MX (2) | MX369768B (ja) |
| NZ (1) | NZ702369A (ja) |
| SG (1) | SG11201407880QA (ja) |
| WO (1) | WO2013181639A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102483419B (zh) | 2009-05-11 | 2017-12-15 | 博格有限责任公司 | 利用表观代谢转变剂、多维细胞内分子或环境影响剂诊断代谢障碍的方法 |
| AU2012240222B2 (en) | 2011-04-04 | 2017-04-27 | Berg Llc | Methods of treating central nervous system tumors |
| EA032345B1 (ru) * | 2012-06-01 | 2019-05-31 | Берг Ллк | Способ лечения рака с использованием кофермента q10 |
| AU2014251045B2 (en) | 2013-04-08 | 2019-06-13 | Berg Llc | Treatment of cancer using coenzyme Q10 combination therapies |
| NZ717504A (en) | 2013-09-04 | 2022-07-01 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
| US9996463B2 (en) * | 2015-11-10 | 2018-06-12 | International Business Machines Corporation | Selection and placement of volumes in a storage system using stripes |
| WO2017087576A1 (en) * | 2015-11-16 | 2017-05-26 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| US20170255565A1 (en) * | 2016-03-02 | 2017-09-07 | Intel Corporation | Method and apparatus for providing a contiguously addressable memory region by remapping an address space |
| US20200093751A1 (en) * | 2016-06-28 | 2020-03-26 | Der-Yang Tien | Chemoprotective/chemoactive nanodroplets and methods of use thereof |
| CA3063916A1 (en) * | 2017-05-17 | 2018-11-22 | Berg Llc | Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa |
| CA3239264A1 (en) * | 2021-12-01 | 2023-06-08 | Gambro Lundia Ab | New dialysis fluid |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20070104688A1 (en) | 2003-02-13 | 2007-05-10 | City Of Hope | Small interfering RNA mediated transcriptional gene silencing in mammalian cells |
| WO2005048925A2 (en) * | 2003-11-14 | 2005-06-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds |
| CN110522717A (zh) | 2004-01-22 | 2019-12-03 | 迈阿密大学 | 局部辅酶q10制剂及其使用方法 |
| EP2123266B1 (en) * | 2006-12-06 | 2014-01-15 | Kaneka Corporation | Cancer therapeutic agent and anti-carcinogenic agent |
| MX363435B (es) | 2007-03-22 | 2019-03-22 | Berg Llc | Formulaciones topicas que tienen biodisponibilidad aumentada. |
| EP2217227B1 (en) * | 2007-11-12 | 2013-08-21 | BiPar Sciences, Inc. | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| AU2008340355B2 (en) | 2007-12-04 | 2015-01-22 | Tekmira Pharmaceuticals Corporation | Targeting lipids |
| US8247435B2 (en) * | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| CN102483419B (zh) * | 2009-05-11 | 2017-12-15 | 博格有限责任公司 | 利用表观代谢转变剂、多维细胞内分子或环境影响剂诊断代谢障碍的方法 |
| PT2544663T (pt) * | 2010-03-12 | 2018-04-05 | Berg Llc | Formulações intravenosas de coenzima q10 (coq10) e métodos de uso da mesma |
| US20140239525A1 (en) | 2011-06-17 | 2014-08-28 | Board Of Regents, University Of Texas System | Inhalable pharmaceutical compositions |
| EA032345B1 (ru) * | 2012-06-01 | 2019-05-31 | Берг Ллк | Способ лечения рака с использованием кофермента q10 |
-
2013
- 2013-05-31 EA EA201492187A patent/EA032345B1/ru not_active IP Right Cessation
- 2013-05-31 NZ NZ702369A patent/NZ702369A/en not_active IP Right Cessation
- 2013-05-31 CA CA3090268A patent/CA3090268A1/en not_active Abandoned
- 2013-05-31 MX MX2014014492A patent/MX369768B/es active IP Right Grant
- 2013-05-31 KR KR1020147037100A patent/KR102163948B1/ko active IP Right Grant
- 2013-05-31 KR KR1020207028370A patent/KR20200118233A/ko not_active Application Discontinuation
- 2013-05-31 CA CA2875150A patent/CA2875150C/en active Active
- 2013-05-31 US US13/907,726 patent/US20140017317A1/en not_active Abandoned
- 2013-05-31 WO PCT/US2013/043785 patent/WO2013181639A1/en active Application Filing
- 2013-05-31 ES ES13797642T patent/ES2761449T3/es active Active
- 2013-05-31 CN CN201380040105.3A patent/CN104507308A/zh active Pending
- 2013-05-31 IN IN10734DEN2014 patent/IN2014DN10734A/en unknown
- 2013-05-31 AU AU2013267166A patent/AU2013267166A1/en not_active Abandoned
- 2013-05-31 EP EP13797642.9A patent/EP2854528B8/en active Active
- 2013-05-31 JP JP2015515272A patent/JP6352905B2/ja active Active
- 2013-05-31 BR BR112014029954A patent/BR112014029954A2/pt not_active IP Right Cessation
- 2013-05-31 SG SG11201407880QA patent/SG11201407880QA/en unknown
-
2014
- 2014-11-27 MX MX2019013776A patent/MX2019013776A/es unknown
- 2014-11-30 IL IL236008A patent/IL236008B/en active IP Right Grant
-
2015
- 2015-10-05 HK HK15109710.3A patent/HK1208995A1/xx unknown
-
2016
- 2016-10-10 US US15/289,770 patent/US20170216223A1/en not_active Abandoned
-
2017
- 2017-04-19 AU AU2017202567A patent/AU2017202567B2/en not_active Ceased
-
2018
- 2018-06-07 JP JP2018109093A patent/JP2018168164A/ja not_active Withdrawn
-
2020
- 2020-07-29 JP JP2020127877A patent/JP7225167B2/ja active Active
-
2021
- 2021-05-17 US US17/321,699 patent/US20220096399A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407880QA (en) | Treatment of solid tumors using coenzyme q10 | |
| SG11201407775WA (en) | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta | |
| SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201408261UA (en) | Syringe | |
| SG11201407569PA (en) | Interrogatory cell-based assays for identifying drug-induced toxicity markers | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201909547TA (en) | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201407537YA (en) | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201407370QA (en) | Humanized il-7 rodents | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201408678WA (en) | Catalysts and methods for polyester production | |
| SG11201407819UA (en) | Improved methods of cell culture for adoptive cell therapy | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201805052YA (en) | Therapeutic methods using erythrocytes |